
Shree Surya Surgi Pharma Private Limited
Pharmaceutical trading and distribution of critical care drugs, medical equipment, and surgical instruments.
Pharmaceutical trading and distribution of critical care drugs, medical equipment, and surgical instruments.
Shree Surya Surgi Pharma Private Limited (SSSPPL) is a Private Limited Indian Non-Government Company incorporated in India on 23 December 2010 and has a history of 14 years and four months. Its registered office is in Nashik, Maharashtra, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.30 M and a paid-up capital of Rs 0.23 M.
The company currently has active open charges totaling ₹5.00 M. The company has closed loans amounting to ₹4.00 M, as per Ministry of Corporate Affairs (MCA) records.
Vikrant Suryawanshi, Ratnakar Tukaram, and Kishor Bagde serve as directors at the Company.
Nashik, Maharashtra, India
+91-XXXXXXXXXX
U33111MH2010PTC211320
211320
Private Limited Indian Non-Government Company
23 Dec 2010
30 Sep 2024
31 Mar 2024
Unlisted
Roc Mumbai
Shree Surya Surgi Pharma Private Limited offers a wide range of products and services, including Common Disease Medicines, Pharmaceutical Medicine, Injectable Products, Anti Infective Drugs & Medicines, Remdesivir Injection, Anti Cancer Medicines, Arimidex Tablets, Cardiovascular Drugs & Medication, Cardiac Drugs, Oncology Drug.
Name | Designation | Appointment Date | Status |
---|---|---|---|
Kishor Bagde ![]() | Director | 10-Nov-2012 | Current |
Vikrant Suryawanshi ![]() | Director | 23-Dec-2010 | Current |
Ratnakar Tukaram ![]() | Director | 23-Dec-2010 | Current |
Shree Surya Surgi Pharma Private Limited, for the financial year ended 2023, experienced modest growth in revenue, with a 4.51% increase. The company also saw a slight improvement in profitability, with a 8.29% increase in profit. The company's net worth moved up by a moderate rise of 1.09%.
Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
---|---|---|---|---|---|---|---|
Total Revenue |
| ||||||
Revenue from Operations |
| ||||||
Total Assets |
| ||||||
Profit or Loss |
| ||||||
Net Worth |
| ||||||
EBITDA |
|
In 2023, Shree Surya Surgi Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Vikrant Suryawanshi and Ratnakar Tukaram are mutual person
Vikrant Suryawanshi is a mutual person
Vikrant Suryawanshi and Ratnakar Tukaram are mutual person
Ratnakar Tukaram is a mutual person
Kishor Bagde is a mutual person
₹5.00 M
₹4.00 M
Date | Lender | Amount | Status |
---|---|---|---|
04 Jul 2022 | Others | ₹5.00 M | Open |
10 May 2012 | Others | ₹4.00 M | Satisfied |
Unlock and access historical data on people associated with Shree Surya Surgi Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Gain comprehensive insights into the Deals and Valuation data of Shree Surya Surgi Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Shree Surya Surgi Pharma's trajectory.
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
Shree Surya Surgi Pharma Private Limited last Annual general meeting of members was held on 30 Sep 2024 as per latest MCA records.
Shree Surya Surgi Pharma Private Limited has filed its annual Financial statements for the year ended 31 Mar 2024 with Roc Mumbai.
A charge registered on 10 May 2012 via Charge ID 10443131 with Others was fully satisfied on 18 Oct 2023.
A charge with Others amounted to Rs. 5.00 M with Charge ID 100603310 was registered on 04 Jul 2022.
A charge with Others of Rs. 4.00 M registered on 10 May 2012 with Charge ID 10443131 was modified on 11 Jan 2013.
Kishor Raghunath Bagde was appointed as a Director was appointed as a Director on 10 Nov 2012 & has been associated with this company since 12 years 5 months .
Shree Surya Surgi Pharma Private Limited was incorporated on 23 Dec 2010.
The authorized share capital of Shree Surya Surgi Pharma Private Limited is ₹ 0.30 M and paid-up capital is ₹ 0.23 M.
Currently 3 directors are associated with Shree Surya Surgi Pharma Private Limited.
As per Ministry of Corporate Affairs (Mca), the registered address of Shree Surya Surgi Pharma Private Limited is G-23A Suyojit City Centre Mumbai Old Agra Road, Naka India, Nashik, Maharashtra, 422007.
The corporate identification number (CIN) of Shree Surya Surgi Pharma Private Limited is U33111MH2010PTC211320 and the company number is 211320 as per Ministry of Corporate Affairs (MCA).
According to the financial reports for the fiscal year 2023, the revenue trend for Shree Surya Surgi Pharma Private Limited has risen by 4.51%.
The financial reports for the fiscal year 2023 indicates that The net worth of Shree Surya Surgi Pharma Private Limited has experienced an upsurge of 1.09%.
As per the financial statements for fiscal Year 2023, The total open charges for Shree Surya Surgi Pharma Private Limited amount to ₹ 5.00 M.
The most recent Balance Sheet for Shree Surya Surgi Pharma Private Limited was filed with the ROC on 31 Mar 2024.
Search company & director profiles for free and gain access to critical business data.
SC